Zydus Lifesciences raises buyback price to ₹1,260

What changed in Zydus Lifesciences’ buyback plan

Zydus Lifesciences has revised the terms of its ongoing share buyback after its buyback committee approved changes on Wednesday, May 27, 2026. The company increased the buyback price to ₹1,260 per equity share from the earlier announced ₹1,150. At the same time, it reduced the maximum number of shares it proposes to repurchase. The revised maximum is 87.30 lakh equity shares, down from 95.65 lakh shares earlier. The company said the revised quantity represents up to 0.87% of its total paid-up equity share capital. Zydus also stated that the overall buyback consideration remains unchanged. The buyback will continue to be executed through the tender offer route.

Revised buyback price: from ₹1,150 to ₹1,260

The most visible change is the higher tender offer price. Zydus Lifesciences raised the buyback price by ₹110 per share, to ₹1,260. The earlier plan, announced in May, was to repurchase shares at ₹1,150 each. In one disclosure, the company said the ₹1,260 buyback price represented a 16% premium over its closing price on Monday, May 25. The board had earlier described the ₹1,150 price as a 16.02% premium over the stock’s closing price of ₹991.20 on May 18, 2026. When the buyback was initially described as the company’s biggest-ever, it was also reported to be at nearly a 13% premium over the stock’s previous closing price. These premiums were highlighted as part of the buyback’s terms.

Share count cut to 87.30 lakh, outlay stays at ₹1,100 crore

Alongside the price hike, the maximum buyback quantity was cut. Zydus reduced the maximum shares proposed to be bought back from 95,65,217 equity shares to 87,30,158 equity shares. The company indicated the revised amount corresponds to up to 0.87% of its paid-up equity share capital, compared with the earlier 0.95% figure tied to 95.65 lakh shares. Importantly, Zydus said the total buyback outlay remains capped at up to ₹1,100 crore. The company also reiterated that the buyback will be on a proportionate basis through the tender offer route, in line with the Companies Act, 2013 and SEBI (Buy-Back of Securities) Regulations, 2018.

Tender offer route and proportionate acceptance

Zydus has consistently stated that the buyback will be conducted through the tender offer mechanism rather than open-market purchases. Under the tender route, eligible shareholders can offer shares during the buyback window, and the company accepts shares based on entitlement and proportionate acceptance. The company has referred to SEBI buyback rules as the governing framework for this process. The updates approved by the buyback committee fit within the flexibility the board had provided. Zydus had earlier formed a buyback committee that could increase the buyback price or reduce the number of shares to be bought back up to one day before the record date, without changing the overall buyback size.

Key dates: record date set for May 29

Zydus Lifesciences has fixed May 29, 2026 as the record date to determine shareholder eligibility for the buyback. The company has clarified that only shareholders who hold the shares in their demat accounts as of the record date will be eligible to tender shares. It was also reported that May 27 was the last day to buy the company’s shares to participate in the buyback. This timing matters for investors planning participation, because eligibility is tied to holdings as of the record date rather than the announcement date.

Promoters plan to participate

Promoter group entities of Zydus Lifesciences have communicated their intention to participate in the buyback. According to the company’s regulatory filing referenced in reports, promoter group entities and persons in control submitted communications dated May 19, 2026, expressing their intent to tender shares, subject to applicable regulations. This disclosure is relevant because promoter participation can influence the post-buyback shareholding structure, although the company has framed it within regulatory conditions.

Snapshot: before vs after revisions

How the buyback unfolded this month

The board of Zydus Lifesciences authorised the buyback plan on May 19, 2026. It approved the repurchase of up to 95.65 lakh fully paid-up equity shares (face value ₹1 each) at ₹1,150 per share, payable in cash, for an aggregate amount not exceeding ₹1,100 crore. The company made a public announcement dated May 20, 2026. Later updates included promoter intent to participate, followed by the buyback committee’s changes on May 27. The committee’s decision raised the buyback price while reducing the number of shares, keeping the overall buyback size unchanged.

Market context and why these revisions matter

A higher tender offer price typically increases the per-share payout for tendering shareholders, while a lower maximum share count can affect how many shares get accepted under proportionate allocation. In this case, Zydus has paired the price increase with a reduction in the proposed repurchase quantity, while maintaining the overall cap of ₹1,100 crore. The company’s disclosures also anchor the programme to specific regulatory requirements, including the Companies Act and SEBI buyback regulations. Zydus has previously executed a buyback of ₹600 crore through the tender route at a price of ₹1,005 per share, providing recent historical context for investors tracking capital return actions.

What to watch next

The record date remains May 29, 2026, and participation depends on shareholding as of that date. Zydus has stated that the tender offer route will be used and that the total consideration will not exceed ₹1,100 crore. Investors will watch for remaining procedural disclosures linked to the tender process, including operational details typically associated with buybacks, as and when the company provides them under regulatory timelines.